Basel-based chemical and biotechnology company Lonza has reported 51 per cent growth in net income to SFr301 million ($274.7 million) in 2007.
Earnings before interest and tax grew by 36 per cent to SFr408 million, exceeding analysts' expectations, and Lonza reported a strong improvement in cash flow.
This performance represents a significant strengthening of Lonza's ability to generate further sustainable growth, a company statement said.
The company said its revised growth strategies for the Bioscience, Nutrition Ingredients and Microbial Control units were designed to deliver enhanced returns.
"Lonza continues to successfully achieve critical milestones in its long-term strategic plan," it said.
The board of directors is proposing a dividend of SFr1.75 per share.
In compliance with the JTI standards